Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 7% – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded down 7% during trading on Thursday . The company traded as low as $23.25 and last traded at $23.25. 61,856 shares were traded during trading, a decline of 70% from the average session volume of 205,195 shares. The stock had previously closed at $25.00.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Finally, Oppenheimer raised their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Stock Performance

The firm has a market capitalization of $704.78 million, a P/E ratio of -9.52 and a beta of 1.74. The business’s fifty day moving average price is $26.09 and its two-hundred day moving average price is $26.54.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Quest Partners LLC lifted its stake in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares during the period. SG Americas Securities LLC acquired a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $112,000. The Manufacturers Life Insurance Company acquired a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $236,000. Fred Alger Management LLC lifted its stake in Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after acquiring an additional 3,316 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $265,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.